SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$45.53 USD
+1.33 (3.01%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $45.55 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for SpringWorks Therapeutics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 0 | 0 | 35 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 5 | 0 | 0 | 35 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 348 | 281 | 173 | 81 | 59 |
Income After Depreciation & Amortization | -343 | -281 | -173 | -46 | -59 |
Non-Operating Income | 18 | 3 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -325 | -277 | -174 | -46 | -58 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -325 | -277 | -174 | -46 | -58 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -325 | -277 | -174 | -46 | -58 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -341 | -280 | -173 | -46 | -59 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -343 | -281 | -173 | -46 | -59 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 63.12 | 53.29 | 48.50 | 43.30 | 13.28 |
Diluted EPS Before Non-Recurring Items | -5.15 | -5.21 | -3.59 | -1.05 | -3.55 |
Diluted Net EPS (GAAP) | -5.15 | -5.21 | -3.59 | -1.05 | -3.81 |
Fiscal Year end for SpringWorks Therapeutics falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 5.45 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.42 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 5.03 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 103.49 | 84.00 | 82.85 | 77.70 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -98.46 | -84.00 | -82.85 | -77.70 |
Non-Operating Income | NA | 3.77 | 4.56 | 4.93 | 4.28 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -94.32 | -79.44 | -77.93 | -73.42 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -94.32 | -79.44 | -77.93 | -73.42 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -94.32 | -79.44 | -77.93 | -73.42 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 65.05 | 62.52 | 62.46 | 62.33 |
Diluted EPS Before Non-Recurring Items | NA | -1.44 | -1.27 | -1.25 | -1.18 |
Diluted Net EPS (GAAP) | NA | -1.45 | -1.27 | -1.25 | -1.18 |